SFM
RLAY icon

Sphera Funds Management’s Relay Therapeutics RLAY Stock Holding History

Sphera Funds Management’s Portfolio RLAY Stock Details RLAY Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$4.38M Sell
233,836
-174,600
-43% -$2.53M 0.57% 60
2026
Q1 		$4.06M Buy
+408,436
New +$3.65M 0.65% 57

Other funds holding RLAY

SIAU
SB Investment Advisers (UK) London, United Kingdom $7.66B AUM 20.12% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
CC
Casdin Capital New York $2B AUM 147.21% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
PA
Perceptive Advisors New York $6.66B AUM 360.84% 1-Year Est. Return
CC
Commodore Capital New York $1.68B AUM 375.52% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
NI
Nextech Invest Zurich, Switzerland $2.11B AUM 413.84% 1-Year Est. Return

Sphera Funds Management's RLAY Position: Q2 2026 in Review

Sphera Funds Management reduced its Relay Therapeutics (RLAY) stake by 43% in Q2 2026, selling an estimated $2.53M and leaving 233,836 shares worth $4.38M. The position accounts for 0.57% of the portfolio, ranked #60.

Sphera Funds Management first reported a position in RLAY in Q1 2026 and has held it in 2 quarters since. 260 funds tracked by Wall St. Rank hold RLAY as of Q2 2026.

  • Sphera Funds Management held 233,836 shares of Relay Therapeutics worth $4.38M as of Q2 2026.
  • Sphera Funds Management sold 174,600 Relay Therapeutics shares in Q2 2026, an estimated $2.53M.
  • Relay Therapeutics made up 0.57% of Sphera Funds Management's portfolio in Q2 2026, its #60 holding.
  • Sphera Funds Management first reported a position in Relay Therapeutics in Q1 2026 and has held it in 2 quarters since.
  • 260 funds tracked by Wall St. Rank held Relay Therapeutics as of Q2 2026.

Based on Sphera Funds Management's 13F filing for Q2 2026, filed 14 Aug 2026.